AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25256937 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.1 μg of rhFSH
Number of subjects: 265
Study 25256937 — intervention group
Group type: COMPARATOR
Intervention: 11 μg (150 IU) of follitropin alfa
Number of subjects: 265
Study 25256937 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFSH (various doses)
Number of subjects: 265
Study 25256937 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFSH (highest doses)
Number of subjects: 265
Study 22733160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) therapy with 11.25 mg leuprorelin acetate
Number of subjects: 109
Study 22733160 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD)
Number of subjects: 109
Study 19951314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenwal Amicus Crescendo (AC)
Number of subjects: 91
Study 19951314 — intervention group
Group type: COMPARATOR
Intervention: CaridianBCT Trima Accel (TA)
Number of subjects: 91
Study 19951314 — intervention group
Group type: COMPARATOR
Intervention: Male donors greater than 88 kg using TA
Number of subjects: 91
Study 15722066 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (15 microg of ethinylestradiol and 120 microg of etonogestrel daily)
Number of subjects: 1030
Study 15722066 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (150 microg of levonorgestrel and 30 microg of ethinylestradiol)
Number of subjects: 1030
Study 12432044 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 105
Study 12432044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 10500014 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (5.1 g twice daily)
Number of subjects: 34
Study 10500014 — intervention group
Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 34
Study 8689216 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cytology results from abdominal washings
Number of subjects: 535
Study 8689216 — intervention group
Group type: COMPARATOR
Intervention: Negative cytology results from abdominal washings
Number of subjects: 535
Study 1994013 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic outreach and screening programme
Number of subjects: 0
Study 1994013 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy outcome measures
Number of subjects: 0
Study 1994013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing clinic development
Number of subjects: 0
Study 7152078 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 200 mg
Number of subjects: 0
Study 7152078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31675992 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment video for staff
Number of subjects: 0
Study 31675992 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported data collection prior to randomisation and treatment
Number of subjects: 0
Study 31675992 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of participant dropout due to delays in treatment
Number of subjects: 0
Study 31675992 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangulation of data sources for follow-up
Number of subjects: 0
Study 29909282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking bag
Number of subjects: 40
Study 29909282 — intervention group
Group type: EXPERIMENTAL
Intervention: Blade tenderizer
Number of subjects: 40
Study 29909282 — intervention group
Group type: EXPERIMENTAL
Intervention: Marinade
Number of subjects: 40
Study 29909282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-temperature cooking
Number of subjects: 40
Study 29909282 — intervention group
Group type: EXPERIMENTAL
Intervention: Roast beef (cooked using culinary processes)
Number of subjects: 40
Study 26814240 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD coarse particles 60 mg
Number of subjects: 31
Study 26814240 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD fine particles 60 mg
Number of subjects: 31
Study 26814240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone powder 60 mg
Number of subjects: 31
Study 26814240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26814240 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 31
Study 25453486 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 0.05-0.12mg/kg/day (6-12 years: 1-4mg/day; 13-17 years: 1-7mg/day)
Number of subjects: 272
Study 25453486 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 10-100mg/day
Number of subjects: 272
Study 25453486 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR)
Number of subjects: 272
Study 25453486 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 272
Study 25453486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 21978796 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30
Study 21978796 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 30
Study 19843053 — intervention group
Group type: EXPERIMENTAL
Intervention: Palosuran 125 mg b.i.d. for 4 weeks
Number of subjects: 20
Study 19843053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17264714 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg daily dexibuprofen
Number of subjects: 12
Study 17264714 — intervention group
Group type: COMPARATOR
Intervention: 100 mg daily aspirin
Number of subjects: 12
Study 15891954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide + insulin
Number of subjects: 477
Study 15891954 — intervention group
Group type: COMPARATOR
Intervention: Placebo + insulin
Number of subjects: 477
Study 11976561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment after one month
Number of subjects: 10
Study 11976561 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 10
Study 9670263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial hepatic chemotherapy (IAHC) using IA FUDR
Number of subjects: 0
Study 9670263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial hepatic chemotherapy (IAHC)
Number of subjects: 0
Study 9670263 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated liver perfusion
Number of subjects: 0
Study 9670263 — intervention group
Group type: EXPERIMENTAL
Intervention: New protocols and combinations with systemic chemotherapy
Number of subjects: 0
Study 7614642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg.kg‐1)
Number of subjects: 50
Study 7614642 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4 mg.kg‐1)
Number of subjects: 50
Study 2212090 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX-rinse (0.12%)
Number of subjects: 44
Study 2212090 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX-irrigation (0.06%)
Number of subjects: 44
Study 2212090 — intervention group
Group type: COMPARATOR
Intervention: Placebo-irrigation
Number of subjects: 44
Study 2212090 — intervention group
Group type: COMPARATOR
Intervention: Placebo-rinse
Number of subjects: 44
Study 484813 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 0.5 mg/kg
Number of subjects: 14
Study 484813 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.067 mg/kg
Number of subjects: 14
Study 30682557 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of alcohol use problems
Number of subjects: 243
Study 30682557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime trauma exposure
Number of subjects: 243
Study 30682557 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher manic symptom scores
Number of subjects: 243
Study 30682557 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of alcohol and drug use problems
Number of subjects: 243
Study 30682557 — intervention group
Group type: COMPARATOR
Intervention: Gender
Number of subjects: 243
Study 29061010 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.1 μg·kg(‐1)·min(‐1) (Group S)
Number of subjects: 120
Study 29061010 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 μg·kg(‐1)·min(‐1) (Group L)
Number of subjects: 120
Study 29061010 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 μg·kg(‐1)·min(‐1) + lappaconitine 8 mg (Group G)
Number of subjects: 120
Study 25830364 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 36
Study 24499494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg NRL001 (2 g suppository)
Number of subjects: 26
Study 24499494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21813856 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient fortified biscuits (FB)
Number of subjects: 510
Study 21813856 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus FB
Number of subjects: 510
Study 21813856 — intervention group
Group type: EXPERIMENTAL
Intervention: FB
Number of subjects: 510
Study 21813856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 21813856 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified biscuits
Number of subjects: 510
Study 19901414 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional stenting (PS)
Number of subjects: 1641
Study 19901414 — intervention group
Group type: COMPARATOR
Intervention: Complex stenting strategy (CS)
Number of subjects: 1641
Study 17207668 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A plus OT
Number of subjects: 80
Study 17207668 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A alone
Number of subjects: 80
Study 17207668 — intervention group
Group type: EXPERIMENTAL
Intervention: OT alone
Number of subjects: 80
Study 17207668 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 80
Study 15258003 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.00 dollars incentive
Number of subjects: 199
Study 11526365 — intervention group
Group type: COMPARATOR
Intervention: b-blockade (Metoprolol)
Number of subjects: 3991
Study 9085171 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast media containing ulinastatin (UST)
Number of subjects: 57
Study 9085171 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast media containing prednisolone (PDN)
Number of subjects: 57
Study 9085171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UST and PDN
Number of subjects: 57
Study 9085171 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 8519040 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (ECA) 325 mg/day
Number of subjects: 80
Study 8519040 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered aspirin (BA) 325 mg/day
Number of subjects: 80
Study 8519040 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin (ASA) 325 mg/day
Number of subjects: 80
Study 8519040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8519040 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal mucosa injury (BA, ECA, ASA, placebo)
Number of subjects: 80
Study 3735414 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 100 mg
Number of subjects: 1
Study 3735414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 31752595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for insomnia (CBT-I)
Number of subjects: 5
Study 31041716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (TAS102)
Number of subjects: 0
Study 31041716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29420925 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of HMB-FA
Number of subjects: 23
Study 29420925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study 26959860 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat agency assigned to diabetes
Number of subjects: 422
Study 26959860 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention agency assigned to humans
Number of subjects: 422
Study 26959860 — intervention group
Group type: COMPARATOR
Intervention: Threat agency assigned to humans
Number of subjects: 422
Study 26959860 — intervention group
Group type: COMPARATOR
Intervention: Prevention agency assigned to recommended behaviors
Number of subjects: 422
Study 24684675 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral hernia repair (LVHR) in Tx/IS patients
Number of subjects: 101
Study 24684675 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ventral hernia repair (LVHR) in non-IS patients
Number of subjects: 101
Study 24347766 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching module with video demonstration and practice session before OSPE
Number of subjects: 40
Study 24347766 — intervention group
Group type: COMPARATOR
Intervention: Control group with video demonstration and practice session after OSPE
Number of subjects: 40
Study 20415603 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 20415603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18764978 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release levodopa (CR-LD)
Number of subjects: 14
Study 18764978 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release levodopa (IR-LD)
Number of subjects: 14
Study 11785993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141
Study 11785993 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin
Number of subjects: 10141
Study 10323085 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNOR method staining and morphometric analysis
Number of subjects: 50
Study 7641909 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal monitoring at transport clinic (1.5 +/- 0.8 US measurements)
Number of subjects: 200
Study 7641909 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring at satellite clinics (2.8 +/- 0.9 US measurements)
Number of subjects: 200
Study 7641909 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal monitoring at transport clinic
Number of subjects: 200
Study 7641909 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring at satellite clinics
Number of subjects: 200
Study 2665657 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b conjugate vaccine (standard dose)
Number of subjects: 103
Study 2665657 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b conjugate vaccine (low dose)
Number of subjects: 103
Study 2665657 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria, pertussis, and tetanus and polio vaccines only (Control)
Number of subjects: 103
Study 2665657 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimmunized infants
Number of subjects: 103
Study 1000148 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra interviews designed to increase understanding of illnesses
Number of subjects: 0
Study 1000148 — intervention group
Group type: COMPARATOR
Intervention: Extra placebo interviews about hospital stay
Number of subjects: 0
Study 30357310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD)
Number of subjects: 0
Study 30357310 — intervention group
Group type: COMPARATOR
Intervention: Standard interval 5-fluorouracil/E/C and D
Number of subjects: 0
Study 27129585 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-reduction
Number of subjects: 39
Study 27129585 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-reduction
Number of subjects: 39
Study 27129585 — intervention group
Group type: COMPARATOR
Intervention: No reduction (control)
Number of subjects: 39
Study 25814042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin aerosol (150mg/3ml) administered via the Easynose® device
Number of subjects: 55
Study 25814042 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline aerosol
Number of subjects: 55
Study 23802927 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage‐matched nursing and community intervention (SMN+CI)
Number of subjects: 117
Study 23802927 — intervention group
Group type: COMPARATOR
Intervention: Community intervention (CI)
Number of subjects: 117
Study 23802927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study 21851204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counselling group (NCG)
Number of subjects: 21
Study 21851204 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum group (ALG)
Number of subjects: 21
Study 20168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (stimulating acupoint BL 67 daily for 2 weeks)
Number of subjects: 212
Study 20168104 — intervention group
Group type: COMPARATOR
Intervention: Expectant management care (Control)
Number of subjects: 212
Study 20168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 212
Study 17251178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol combination
Number of subjects: 177
Study 17251178 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 177
Study 15517934 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 32
Study 15517934 — intervention group
Group type: COMPARATOR
Intervention: No-EPO (blood transfusions)
Number of subjects: 32
Study 11182036 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG instillation
Number of subjects: 20
Study 11182036 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin instillation
Number of subjects: 20
Study 9447537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine and prilocaine cream (1 to 1.25 gm)
Number of subjects: 13
Study 9447537 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide placebo
Number of subjects: 13
Study 7942935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 92
Study 7942935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 92
Study 2847676 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at high pressor dose (to increase diastolic pressure by 25 mmHg) in healthy volunteers
Number of subjects: 11
Study 2847676 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in healthy subjects
Number of subjects: 11
Study 2847676 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in patients with mild essential hypertension
Number of subjects: 11
Study 30433852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus cisplatin and radiation twice a day (FCT)
Number of subjects: 66
Study 30433852 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily radiation plus gemcitabine (GD)
Number of subjects: 66
Study 26838529 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Number of subjects: 24
Study 26838529 — intervention group
Group type: COMPARATOR
Intervention: Intralipid
Number of subjects: 24
Study 26838529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 25816746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1WS: one 60‐min supervised session/week
Number of subjects: 573
Study 25816746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3WS: three 20‐min supervised sessions/week
Number of subjects: 573
Study 25816746 — intervention group
Group type: EXPERIMENTAL
Intervention: 9WS: nine 7‐min supervised sessions/week
Number of subjects: 573
Study 25816746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MS: three 20‐min sessions/week with minimal supervision
Number of subjects: 573
Study 25816746 — intervention group
Group type: COMPARATOR
Intervention: REF: reference group without training
Number of subjects: 573
Study 23744847 — intervention group
Group type: EXPERIMENTAL
Intervention: HES group (hydroxyethyl starch 130/0.4)
Number of subjects: 60
Study 23744847 — intervention group
Group type: COMPARATOR
Intervention: Gelo group (gelatin)
Number of subjects: 60
Study 23744847 — intervention group
Group type: EXPERIMENTAL
Intervention: HES group
Number of subjects: 60
Study 23744847 — intervention group
Group type: COMPARATOR
Intervention: Gelo group
Number of subjects: 60
Study 19207485 — intervention group
Group type: EXPERIMENTAL
Intervention: HybenX
Number of subjects: 63
Study 19207485 — intervention group
Group type: COMPARATOR
Intervention: Salicept
Number of subjects: 63
Study 18021576 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 898
Study 18021576 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 898
Study 18021576 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Echo
Number of subjects: 898
Study 18021576 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 898
Study 15098804 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT before WHI (July 9, 2001 - January 9, 2002)
Number of subjects: 98
Study 15098804 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT after WHI (July 9, 2002 - January 9, 2003)
Number of subjects: 98
Study 15098804 — intervention group
Group type: COMPARATOR
Intervention: Pre-WHI group (randomized)
Number of subjects: 98
Study 15098804 — intervention group
Group type: COMPARATOR
Intervention: Post-WHI group (randomized)
Number of subjects: 98
Study 11565624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg on days 1-7, 100 mg on days 8-14)
Number of subjects: 24
Study 11565624 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg on days 1-7, 40 mg on days 8-14)
Number of subjects: 24
Study 11565624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9630155 — intervention group
Group type: EXPERIMENTAL
Intervention: Single transperineal injection of botulinum toxin
Number of subjects: 5
Study 7943829 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.15 mg.kg-1
Number of subjects: 256
Study 7943829 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide 0.5 mg.kg-1
Number of subjects: 256
Study 7943829 — intervention group
Group type: COMPARATOR
Intervention: droperidol 0.075 mg.kg-1
Number of subjects: 256